tiprankstipranks
Advertisement
Advertisement

CTOR Stock Latest News

Citius Oncology highlights early LYMPHIR commercial traction, expansion
Company AnnouncementsCitius Oncology highlights early LYMPHIR commercial traction, expansion
17d ago
8K
CTOR
Citius Oncology provides commercial update on lymphir launch
PremiumThe Fly
Citius Oncology provides commercial update on lymphir launch
17d ago
CTOR
Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data
PremiumCompany Announcements
Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data
1M ago
8K
CTOR
Citius Oncology’s Lymphir shows positive results in gynecologic cancers
PremiumThe Fly
Citius Oncology’s Lymphir shows positive results in gynecologic cancers
1M ago
CTOR
Citius Oncology Announces Positive Phase 1 LYMPHIR Data
PremiumCompany Announcements
Citius Oncology Announces Positive Phase 1 LYMPHIR Data
1M ago
8K
CTOR
Citius Oncology reports results from Phase 1 trial evaluating LYMPHIR
PremiumThe FlyCitius Oncology reports results from Phase 1 trial evaluating LYMPHIR
1M ago
CTOR
Citius Oncology reports Q1 EPS (6c) vs. (9c) last year
Premium
The Fly
Citius Oncology reports Q1 EPS (6c) vs. (9c) last year
2M ago
CTOR
CTXR
Citius Pharmaceuticals reports $3.9M in revenue following launch of Lymphir
Premium
The Fly
Citius Pharmaceuticals reports $3.9M in revenue following launch of Lymphir
2M ago
CTOR
CTXR
Citius Pharmaceuticals reports Q1 EPS (41c) vs. ($1.30) last year
PremiumThe Fly
Citius Pharmaceuticals reports Q1 EPS (41c) vs. ($1.30) last year
2M ago
CTOR
CTXR
CTOR Earnings this Week: How Will it Perform?
PremiumPre-Earnings
CTOR Earnings this Week: How Will it Perform?
2M ago
CTOR
Citius files to sell shares of common stock underlying warrants for holders
PremiumThe Fly
Citius files to sell shares of common stock underlying warrants for holders
3M ago
CTOR
Citius Oncology’s LYMPHIR FDA Win Clouded by High Upfront Costs, Regulatory Risks, and Uncertain Market Adoption
PremiumCompany Announcements
Citius Oncology’s LYMPHIR FDA Win Clouded by High Upfront Costs, Regulatory Risks, and Uncertain Market Adoption
4M ago
CTOR
Citius Oncology reports FY25 EPS (34c) vs. (31c) last year
PremiumThe FlyCitius Oncology reports FY25 EPS (34c) vs. (31c) last year
4M ago
CTOR
Citius Oncology Raises $18M Through Direct Offering
Premium
Company Announcements
Citius Oncology Raises $18M Through Direct Offering
4M ago
8K
CTOR
Citius Oncology to sell 1.28M shares at $1.09 in registered direct offering
Premium
The Fly
Citius Oncology to sell 1.28M shares at $1.09 in registered direct offering
4M ago
CTOR
CTXR
Citius Oncology expands Lymphir distribution to Turkey and Middle East
PremiumThe Fly
Citius Oncology expands Lymphir distribution to Turkey and Middle East
4M ago
CTOR
Citius Oncology Launches LYMPHIR for Cutaneous T-Cell Lymphoma
PremiumCompany Announcements
Citius Oncology Launches LYMPHIR for Cutaneous T-Cell Lymphoma
5M ago
8K
CTOR
Citius Oncology announces U.S. commercial launch of LYMPHIR
PremiumThe Fly
Citius Oncology announces U.S. commercial launch of LYMPHIR
5M ago
CTOR
Citius Oncology to advance launch of Lymphir with Verix AI integration
PremiumThe Fly
Citius Oncology to advance launch of Lymphir with Verix AI integration
5M ago
CTOR
CTXR
Citius Oncology Stockholders Approve Share Increase
PremiumCompany AnnouncementsCitius Oncology Stockholders Approve Share Increase
6M ago
8K
CTOR
Citius Oncology Prepares LYMPHIR Launch for Q4 2025
Premium
Company Announcements
Citius Oncology Prepares LYMPHIR Launch for Q4 2025
6M ago
8K
CTOR
Citius Oncology announces distribution agreement with McKesson
Premium
The Fly
Citius Oncology announces distribution agreement with McKesson
6M ago
MCK
CTOR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >